Has Karen McGuire received payments from drug or device companies?

Yes. Drug and device makers reported $4,399 in general payments to Karen McGuire across 205 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Karen McGuire did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Karen McGuire come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Karen McGuire

Family · Lake Jackson, TXNPI 1598530115

Payments from drug & device makers

$4,399in general payments, 2019–2025

Across 205 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$874
Sanofi$522
GSK$370
Takeda Pharmaceuticals U.S.A., Inc.$351
LEO Pharma Inc.$269
Pharming Healthcare, Inc.$267
plus $2K from 21 others

What the payments were for

Food & beverage$4,31898%
Education$812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	31	$874
Sanofi	21	$522
GSK	31	$370
Takeda Pharmaceuticals U.S.A., Inc.	16	$351
LEO Pharma Inc.	18	$269
Pharming Healthcare, Inc.	13	$267
Regeneron Healthcare Solutions, Inc.	8	$261
Genentech USA, Inc.	13	$250
CSL Behring	8	$223
Blueprint Medicines Corporation	4	$115
AbbVie	6	$115
Amgen	5	$95
Novartis	3	$80
ARS Pharmaceuticals Operations, Inc.	3	$70
Kaleo, Inc.	3	$61
Ionis Pharmaceuticals, Inc.	2	$58
Optinose US, Inc.	2	$58
Sanofi-aventis U.S. LLC	1	$55
Tersera Therapeutics LLC	2	$50
Galderma Laboratories, L.p.	3	$47
Aytu Biopharma, Inc.	3	$46
Verona Pharma, Inc.	2	$46
Grifols USA, LLC	2	$31
Lilly USA, LLC	2	$30
X4 Pharmaceuticals, Inc.	1	$20
Hikma Pharmaceuticals USA	1	$19
Invivyd Inc	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEZSPIRE$240

How this compares

$4,399 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OrladeyoBerotralstat Hydrochloride	15	$661,164
Breo ElliptaFluticasone/Vilanterol	14	$5,202
Advair HfaFluticasone Propion/Salmeterol	11	$4,652
Epinephrine	19	$3,622
Albuterol Sulfate HfaAlbuterol Sulfate	19	$556
Fluticasone Propionate	11	$239
Doxycycline Monohydrate	19	$209
Montelukast Sodium	14	$134
Azithromycin	31	$106
Prednisone	17	$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKBreo Ellipta	$370	$5,20214 claims
Hikma Pharmaceuticals USAEpinephrine	$19	$3,62219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Lake Jackson

Lashonda CraneHouston$3.4M
David WeirDallas$959K
Luba YammineHouston$479K
Robin BeachHouston$428K
Nirupama JeromeAustin$418K
April LopezMcAllen$417K
Linda MercadoHouston$211K
Sarah AguilarHouston$199K
Sie ThomasDallas$197K
Anna CastroSan Antonio$184K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →